Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207116 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Neoplasm Metastasis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00207116 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Neoplasm Metastasis that has completed, run by Eli Lilly and Company. The registered enrollment target is 120 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00207116, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Neoplasm Metastasis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
Conditions Studied
Interventions
- DRUG Cetuximab
Study Locations (1)
Delaware
- Local Institution - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207116
The ClinicalTrials.gov registry entry for NCT00207116 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (63% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Cetuximab is the first listed.
NCT00207116 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT00207116 about?
NCT00207116 is a clinical study titled "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma". The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
What is the current status of trial NCT00207116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2005-09. Estimated completion is 2006-03.
What conditions does trial NCT00207116 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Neoplasm Metastasis.
What interventions are being tested in trial NCT00207116?
The interventions under investigation include: Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00207116?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00207116 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.